Dulaglutide protected against diabetic kidney disease in rats by improving kidney function, boosting antioxidant defenses, and reducing inflammation, with cilostazol further enhancing these protective effects.
Multi-pathway kidney protectionDulaglutide protected diabetic kidneys through increased eNOS expression, decreased NF-κB signaling, enhanced antioxidant markers, and improved histopathology — with cilostazol providing additional benefit.
What the researchers found
In 60 diabetic rats, both dulaglutide and metformin significantly decreased blood pressure, blood glucose, serum lipids, and improved kidney functional parameters compared to untreated diabetic controls. These improvements were associated with increased antioxidant markers, decreased inflammatory markers (NF-κB gene expression), and reduced fibrotic changes in kidney tissue.
Adding cilostazol to either dulaglutide or metformin further enhanced some antioxidant and anti-inflammatory properties. Histopathological examination confirmed that treated groups had improved kidney tissue architecture compared to untreated diabetic rats. Dulaglutide also increased eNOS gene expression in kidney tissue, suggesting improved vascular function.
Why it matters
Diabetic kidney disease affects about 40% of diabetes patients and is the leading cause of end-stage renal disease. GLP-1 drugs like dulaglutide are already showing kidney-protective effects in human trials, and this study helps explain why — through antioxidant, anti-inflammatory, and anti-fibrotic mechanisms. The potential synergy with cilostazol could offer an enhanced combination strategy for kidney protection in diabetic patients.
How the study worked
Sixty male albino rats with induced type 2 diabetes were randomly divided into 5 groups: untreated diabetic controls, and four treatment groups receiving metformin, dulaglutide, metformin + cilostazol, or dulaglutide + cilostazol. After the treatment period, researchers measured body weight, blood pressure, fasting blood glucose, lipid profiles, and kidney function markers. Kidney tissue was analyzed for eNOS and NF-κB gene expression and examined histopathologically.
What this study cannot tell us
This is a rat model of induced diabetes, which may not perfectly replicate human diabetic kidney disease. The study did not report specific numerical values for kidney function markers in the abstract. The duration of treatment was not specified. Cilostazol's additive benefits appeared to be partial rather than dramatic. The mechanism linking cilostazol's anti-platelet effects to improved kidney antioxidant properties needs further investigation.
How to read the evidence
This is a preclinical animal study in induced-diabetes rats. While it provides useful mechanistic data supporting GLP-1 renoprotection, translation to human clinical practice requires validation. The broader GLP-1 renoprotection story is supported by human clinical trial data from other studies.
When this study was published
Published in 2022, this study adds mechanistic support to the growing evidence that GLP-1 drugs protect kidneys in diabetes. Subsequent large human trials have increasingly confirmed renoprotective effects of GLP-1 agonists.
The bigger picture
Large human trials (AWARD, AMPLITUDE-O) have shown that GLP-1 drugs protect kidneys in type 2 diabetes. This animal study adds mechanistic understanding — showing that kidney protection involves antioxidant defense activation, inflammation suppression, improved endothelial function (eNOS), and reduced fibrosis. The cilostazol combination finding is novel and could lead to clinical testing of this specific drug pairing.
Questions still open
- Would the dulaglutide-cilostazol combination show enhanced kidney protection in human diabetic kidney disease patients?
- How do the renoprotective mechanisms of dulaglutide compare to those of semaglutide or tirzepatide?
- Does the eNOS upregulation by dulaglutide improve glomerular filtration through vasodilation of renal arterioles?
Common questions
How does dulaglutide protect the kidneys in diabetes?
What is cilostazol and why was it added to the treatment?
Read the original research
Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.
Iranian journal of basic medical sciences, 25(12), 1487-1497
Citation
El Amin Ali, Amani M; Osman, Hamed M; Zaki, Azaa M; Shaker, Olfat; Elsayed, Asma Mohammed; Abdelwahed, Mostafa Yehia; Mohammed, Rahab Ahmed. (2022). Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.. Iranian journal of basic medical sciences, 25(12), 1487-1497. https://doi.org/10.22038/IJBMS.2022.65061.14494